Tissue Penetration of Antibiotics in Obesity

The purpose of this study is to evaluate cefoxitin pharmacokinetics in obese surgical patients.

Completed

Looking for future studies?

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Barnes Jewish Hospital

St Louis, Missouri, 63110, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BMI <25 and >40
Scheduled for elective abdominal or pelvic surgery
Surgical plan for intraoperative cefoxitin prophylaxis
Able to provide informed consent

Exclusion criteria

Allergy to Cefoxitin
Renal or Hepatic insufficiency

Treatment and study plan

Primary outcomes

Cefoxitin Plasma Concentrations

Time frame: 8 hours

Cefoxitin plasma concentrations

Secondary outcomes

Cefoxitin Tissue Concentrations

Time frame: 8 hours

Cefoxitin tissue concentrations

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Important dates

Study start: 2008
Primary completion: 2011
Study completion: 2011
First posted: Sep 16, 2008
Registry last updated: Sep 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed